Kupando develops therapies addressing unmet needs in cancer and infectious diseases by harnessing innate immune stimulation and induction of trained innate immunity via dual Toll‑Like Receptor (TLR) agonists. Its lead candidate, KUP101, is a differentiated dual TLR4 and TLR7 agonist with a preclinical profile and a stated clear path to the clinic. The company plans to use the newly raised Series A funds to advance KUP101’s Phase 1b clinical study in advanced solid tumors and to accelerate its infectious‑disease preclinical programs. Kupando is led by CEO and Founder Johanna Holldack and is based in Schönefeld, Germany. Financially, the latest €10M Series A tranche brought the total capital raised to $23M.

Total raised

$24M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2026